Latest news with #Trevi
Yahoo
a day ago
- Business
- Yahoo
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
NEW HAVEN, Conn., June 2, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. All of the shares in the offering are being offered by Trevi. In addition, Trevi expects to grant the underwriters a 30-day option to purchase up to an additional $15,000,000 of the shares of its common stock sold in the public offering at the public offering price, less underwriting discounts and commissions. Morgan Stanley, Leerink Partners, Stifel and Cantor are acting as joint book-running managers for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. The shares are being offered by Trevi pursuant to a shelf registration statement on Form S-3 (File No. 333-273030), which was filed with the Securities and Exchange Commission (SEC) on June 29, 2023, amended on August 11, 2023 and declared effective by the SEC on August 15, 2023. This offering is being made only by means of a prospectus supplement and the accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement relating to and describing the terms of the offering is expected to be filed with the SEC and, when filed, copies of the preliminary prospectus supplement relating to and describing the offering may be obtained for free by visiting the SEC's website at Copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@ Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@ Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@ or from Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, New York 10022, or by email at prospectus@ final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC. This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease (ILD) and in patients with refractory chronic cough (RCC). Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements about the anticipated public offering and the expected size of the offering, and other statements containing the words "believes," "anticipates," "plans," "expects," "may," and similar expressions. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, as well as other risks and uncertainties, set forth in the "Risk Factors" section of the preliminary prospectus supplement to be filed with the SEC, in Trevi's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the SEC, and in any subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trevi undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made except as required by law. Investor ContactJonathan CarlsonTrevi Therapeutics, Inc.(203) 654 3286carlsonj@ Media ContactRosalia Scampoli914-815-1465rscampoli@ View original content to download multimedia: SOURCE Trevi Therapeutics, Inc.
Yahoo
2 days ago
- Business
- Yahoo
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p<0.0001; 27 mg BID p<0.01); a -43.3% placebo-adjusted change from Baseline was achieved at the 108 mg BID dose group Patients saw a rapid reduction in 24-hour cough frequency at Week 2, the first time point measured Haduvio was generally well-tolerated at all doses; discontinuation rates due to adverse events were similar in the Haduvio and placebo groups, 5.6% and 5.0%, respectively Trevi plans to request an End-of-Phase 2 meeting with the FDA later this year and is planning to initiate the Phase 3 program in the first half of 2026 Company to host a conference call and webcast today at 8:30 a.m. ET and will be joined by the study's UK Lead Investigator, Professor Philip Molyneaux NEW HAVEN, Conn., June 2, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), is pleased to announce today positive topline results from its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with IPF (N=165). The primary endpoint in the CORAL trial was achieved, demonstrating statistically significant reductions in 24-hour cough frequency across all dose groups at Week 6. The 108 mg BID, 54 mg BID and 27 mg BID dose groups achieved reductions from Baseline of 60.2% (p<0.0001), 53.4% (p<0.0001), and 47.9% (p<0.01), respectively, compared to a placebo reduction from Baseline of 16.9%1. Statistically significant improvements were observed across secondary endpoints at Week 6 in the 108 mg BID and 54 mg BID dose groups. "The CORAL trial is the first positive Phase 2b parallel group study for the treatment of chronic cough in patients with IPF, a significant milestone for patients and Trevi," said Jennifer Good, President and CEO of Trevi Therapeutics. "Chronic cough is one of the most debilitating comorbidities for patients with IPF, impacting an estimated 85% of these patients. There are no approved therapies for chronic cough in this population and with these data, Trevi is one step closer to addressing this unmet need." "In my patients with IPF, chronic cough is one of the most challenging comorbidities I face clinically," said Philip Molyneaux, MD, Professor of Pulmonary Medicine at the Royal Brompton Hospital, London. "IPF treatments focus on slowing disease progression but have not shown benefit on chronic cough, which can lead to poor health outcomes and quality of life. I am excited about the CORAL data and the potential continued development of nalbuphine ER for this significant unmet need among IPF patients." Primary Endpoint – Relative Change from Baseline in 24-hour Cough Frequency (coughs per hour) at Week 6Placebo1 (N=39) Haduvio 27 mg BID (N=42) Haduvio 54 mg BID (N=43) Haduvio 108 mg BID (N=40) Baseline 24-hour Cough Frequency (coughs/hour) 29.4 24.6 28.0 31.5 Relative Change from Baseline in 24-hour Cough Frequency at Week 6 -16.9 % -47.9% (p<0.01) -53.4% (p<0.0001) -60.2% (p<0.0001) Placebo-adjusted difference - -30.9 % -36.5 % -43.3 %1One placebo patient with an extreme outlier value at Week 6 was excluded from the modified intent-to-treat (mITT) population. Inclusion of the patient in the placebo group would have resulted in an increased cough frequency from Baseline in the placebo group and much greater placebo-adjusted differences. The primary efficacy endpoint was the relative change in objective 24-hour cough frequency (coughs per hour) for the mITT population at the end of Week 6 versus Baseline for Haduvio compared to placebo. The mITT population consists of all randomized patients who received at least one dose of study drug or placebo. Additional Trial Results A rapid reduction was seen in 24-hour cough frequency at Week 2 with Haduvio, the first time point measured. A 50% reduction in 24-hour cough frequency at Week 6 vs Baseline was seen in 65% of patients on 108 mg BID Haduvio (p<0.001), 63% of patients on 54 mg BID Haduvio (p<0.001) and 60% of patients on 27 mg BID Haduvio (p<0.001) dose groups, compared to 19% of placebo patients. A statistically-significant response was observed on the cough-severity numerical rating scale (CS-NRS), a secondary endpoint, at Week 6 on Haduvio in both the 108 mg BID and 54 mg BID dose groups. There was a mean reduction on a 0 – 10 scale of 3.0 points on the 108 mg BID (p<0.05), 3.2 points on the 54 mg BID (p<0.01) and 2.0 points on the 27 mg BID (p=0.46) dose groups compared to a 1.5-point reduction on placebo at Week 6. The 108 mg BID and 54 mg BID dose groups were statistically-significant (p<0.01) on the patient-reported outcome E-RS®: IPF Cough Subscale, a secondary endpoint, with mean relative change from Baseline of -42.4% and -43.1%, respectively at Week 6, compared to -23% for those on placebo at Week 6. The 27 mg BID dose group was not statistically-significant with a mean relative change from Baseline of –31.6%. Discontinuation rates due to adverse events were similar in the combined Haduvio groups (5.6%) and placebo group (5.0%). The safety profile observed in the trial was generally consistent with the known safety profile of Haduvio from previous trials. The most common adverse events experienced included: nausea, vomiting, constipation, dizziness, headache, fatigue, somnolence, and dry mouth. Serious adverse events (all non-fatal) were reported for four patients (10.0%) in the placebo group and for two patients (1.6%) across all Haduvio doses combined. James Cassella, Ph.D., Chief Development Officer of Trevi Therapeutics added, "We are very pleased with the findings from the CORAL trial, which continue to demonstrate the robust cough suppressant activity of nalbuphine ER. The study has provided critical dose-ranging data to inform the planning of our Phase 3 program. We intend to request an End-of-Phase 2 meeting with the FDA to discuss our plans for initiating the Phase 3 program for the treatment of chronic cough in patients with IPF. I would like to take the opportunity to thank the patients, investigators and site staff for moving research forward for these patients. We look forward to advancing development of this program." Conference Call/Webcast The Company will host a conference call and webcast to review the topline results today, June 2nd, at 8:30 a.m. ET. The live webcast, including audio and presentation slides, will be accessible at the time of the meeting and can be accessed here. To participate in the live conference call by phone, please dial (877) 870 4263 (domestic) or (412) 317 0790 (international) and ask to join the Trevi Therapeutics call. No code is necessary for access. An archived replay of the webcast will also be available for 30 days on the Company's website following the event. About the CORAL TrialThe Phase 2b Cough Reduction in IPF with Nalbuphine ER (CORAL) trial was a double-blind, randomized, placebo-controlled, parallel-arm trial evaluating three doses of Haduvio (27 mg, 54 mg, and 108 mg twice daily) compared to placebo for the treatment of chronic cough in patients with IPF over a 6-week treatment period. 165 patients with IPF chronic cough were randomized 1:1:1:1 to one of three Haduvio doses or placebo with an initial 2-week titration period to the target dose followed by 4 weeks of fixed dosing. The primary efficacy endpoint for the trial was the relative change in 24-hour cough frequency (coughs per hour), as determined by an objective cough monitor, for the modified intent-to-treat (mITT) population at the end of Week 6 versus Baseline for Haduvio compared to placebo. The mITT population consisted of all patients who were randomized and received at least one dose of study drug or placebo. About Idiopathic Pulmonary Fibrosis (IPF) Chronic CoughChronic cough is a highly prevalent condition in patients with IPF, impacting up to 85% of the IPF population. There are ~140,000 patients in the U.S. with IPF. The impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients. About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. For more information, visit and follow Trevi on X (formerly Twitter) and LinkedIn. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding Trevi's business plans and objectives, including future plans or expectations for Haduvio and plans and timing with respect to clinical trials and clinical data and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties regarding the success, cost and timing of Trevi's product candidate development activities and clinical trials; the risk that positive data from a clinical trial may not necessarily be predictive of the results of later clinical trials in the same or a different indication; uncertainties regarding Trevi's ability to execute on its strategy; uncertainties with respect to regulatory authorities' views as to the data from Trevi's clinical trials and next steps in the development path for Haduvio in the United States and foreign countries; uncertainties inherent in estimating Trevi's cash runway, future expenses and other financial results, including Trevi's ability to fund future operations, including clinical trials, as well as other risks and uncertainties set forth in the quarterly report on Form 10-Q for the quarter ended March 31, 2025 filed with the Securities and Exchange Commission and in subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trevi undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Contact Jonathan CarlsonTrevi Therapeutics, Inc.(203) 654 3286carlsonj@ Media Contact Rosalia Scampoli914-815-1465rscampoli@ 2Evaluating Respiratory Symptoms in Idiopathic Pulmonary Fibrosis as collected in the EXACT® (EXAcerbation of Chronic pulmonary disease Tool). EXACT© 2013, Evidera, Inc. All rights reserved. View original content to download multimedia: SOURCE Trevi Therapeutics, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Malaysian Reserve
2 days ago
- Health
- Malaysian Reserve
Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn., June 1, 2025 /PRNewswire/ — Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced a conference call and live webcast taking place tomorrow, Monday, June 2nd, 2025, at 8:30 a.m. ET, to share topline results from the Phase 2b CORAL trial of Haduvio in patients with IPF chronic cough. Conference Call/WebcastThe Company will host a conference call and webcast to review the topline results. The live webcast, including audio and presentation slides, will be accessible at the time of the meeting and can be accessed here. To participate in the live conference call by phone, please dial (877) 870 4263 (domestic) or (412) 317 0790 (international) and ask to join the Trevi Therapeutics call. No code is necessary for access. An archived replay of the webcast will also be available for 30 days on the Company's website following the event. About Idiopathic Pulmonary Fibrosis (IPF) Chronic CoughChronic cough is a highly prevalent condition in patients with IPF, impacting up to 85% of the IPF population. There are ~140,000 patients in the U.S. with IPF. The impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients' social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients. About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC). Haduvio is the first and only investigational therapy to show a statistically-significant reduction in cough frequency in clinical trials of patients with IPF chronic cough and in patients with RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), targeting opioid receptors that play a key role in controlling chronic cough. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency. Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority. For more information, visit and follow Trevi on X (formerly Twitter) and LinkedIn. Investor ContactJonathan CarlsonTrevi Therapeutics, Inc.(203) 654 3286carlsonj@ Media ContactRosalia Scampoli914-815-1465rscampoli@
Zawya
20-05-2025
- Business
- Zawya
Egypt: Trevi targets 11.4mln users, CEO reveals ambitious growth
Arab Finance: Egypt's fintech sector is growing remarkably, solidifying its position as a key player in the Middle East and North Africa (MENA). The country boasts a vibrant ecosystem of over 177 startups and payment service providers, marking a remarkable 5.5-fold increase in the past five years, according to the FinTech Landscape report issued by Entlaq. These companies operate across diverse subsectors, including lending, payments, and business-to-business (B2B) marketplaces. This reflects the increasing adoption of digital financial services in Egypt. Amid this rapid fintech evolution, we spoke to with Antony Sobhy, CEO of Trevi, a Cairo-based fintech startup. Trevi is redefining personal finance by integrating digital payments, loyalty rewards, lending, and personal finance management into a single, AI-powered platform. This exclusive interview offers valuable insights into the strategies and innovations driving this dynamic industry. 1-What inspired you to create Trevi, and how does it differentiate itself from other digital payment and loyalty apps on the market? The inspiration for Trevi stemmed from recognizing how fragmented and overwhelming personal finance can be for everyday users. Most apps tend to focus on a single aspect, whether it is payments, loyalty programs, or budgeting, but very few offer a cohesive experience that brings these tools together. Trevi sets itself apart by serving as a comprehensive, AI-powered financial platform that seamlessly integrates digital payments, loyalty rewards, lending, and personal finance management. Our emphasis is on personalization and providing practical tools that empower users to make smarter financial decisions, not just facilitate transactions. 2-You have emphasized Trevi as an "all-in-one platform." What key financial and investment needs does Trevi address that other apps might overlook? Trevi supports a broad spectrum of financial needs, from everyday spending and family budgeting to saving, lending, and investing. Unlike many apps, we leverage AI and behavioral data to provide real-time insights, predictive budgeting, and personalized financial recommendations. Trevi also fills critical gaps in the market by offering features such as family wallets, 'save now, pay later' options, and embedded lending. Our goal is to empower users to optimize their spending and build wealth, all within a single, unified platform. 3-The Family Wallet is one of Trevi's standout features. How does it help households manage their finances more effectively? And what user feedback have you received on this feature? The Family Wallet is designed to help households consolidate spending, set budgets, and track expenses across all family members. Parents can allocate allowances, monitor children's transactions, and set shared savings goals to promote financial awareness and discipline at home. Based on our research and user group surveys, families see great value in having a centralized tool that encourages transparency, responsible spending, and better financial communication. It is especially appealing for parents looking to instill smart money habits in their children while maintaining full visibility and control. 4-Upcoming features like 'Save Now, Pay Later' (SNPL) and 'Lending & Leasing' services sound innovative. How do these features address current economic challenges like inflation? With inflation, managing cash flow and planning big purchases is more critical than ever. SNPL allows users to set aside funds over time for major expenses, avoiding high-interest debt. Meanwhile, our Lending & Leasing services use AI-powered risk assessment to offer fair, flexible financing. These features give users more control, reduce financial stress, and help them navigate the pressures of rising costs without falling into debt traps. 5-You have partnered with Paymob to support various payment methods, including NFC integration soon. How do these partnerships enhance Trevi's capabilities? Partnering with Paymob and other leading providers enables Trevi to offer the broadest possible range of secure, convenient payment options, from card payments and QR to NFC and beyond. These integrations ensure our users can pay however and wherever they want, while keeping transactions smooth and secure. It also positions Trevi as a forward-thinking platform ready for future innovations in payments technology. 6-With Egypt's fintech market projected to reach $157.86 billion by 2029, what opportunities do you see for Trevi in this rapidly growing sector? Egypt's booming fintech market is a huge opportunity for Trevi to reach millions of underserved consumers with our all-in-one approach. As digital adoption accelerates, there is a clear demand for platforms that make money management simpler, smarter, and more accessible. Trevi is uniquely positioned to lead this transformation by combining payments, savings, lending, and loyalty in a single, AI-driven app. 7-You have set a target of 11.4 million users in five years. What strategies will Trevi employ to achieve this ambitious user acquisition goal? To reach 11.4 million users, we are focused on strategic partnerships with leading merchants, banks, and fintechs to drive adoption at scale. We are also investing in community engagement, referral incentives, and localized campaigns. Our platform's flexibility lets us tailor features to different user segments, and our data-driven approach enables continuous optimization of our acquisition strategies. 8-Trevi plans to expand into the GCC and the North Africa, Levant, and Pakistan (NALP) regions, including countries like Saudi Arabia, UAE, and Morocco. What strategies are you employing to adapt to these diverse markets? We recognize that each market is unique, so we are adapting Trevi's offerings to local regulatory, cultural, and consumer needs. This means partnering with local financial institutions, ensuring compliance, and providing multi-language support. Our modular platform allows us to quickly localize features, payment methods, and rewards to ensure relevance and value in every region we enter. 9-What challenges do you anticipate as you expand regionally, and how is Trevi preparing to overcome them? Key challenges include regulatory compliance, market competition, and building local trust. We proactively engage with regulators, build strong local partnerships, and invest in customer education. Our scalable technology and agile team mean we can adapt quickly to market feedback and regulatory changes, ensuring we stay ahead as we grow. 10-How do you ensure that Trevi remains secure while offering seamless transactions across various payment methods? Security is a top priority at Trevi. We use end-to-end encryption, real-time fraud detection, and rigorous compliance protocols to keep user data and transactions safe. Regular security audits and partnerships with top-tier payment providers mean users can trust Trevi for both convenience and peace of mind. 11-Looking ahead, what is Trevi financial goals for 2025 in terms of revenue generation and profits? For 2025, our primary goal is to achieve sustainable, scalable growth. We aim to significantly increase our user base, drive transaction volume, and expand our revenue streams through value-added services like lending, savings, and merchant partnerships. Profitability is in focus, but we are prioritizing long-term growth and market leadership as the foundation for Trevi's success. © 2020-2023 Arab Finance For Information Technology. All Rights Reserved. Provided by SyndiGate Media Inc. (
Yahoo
06-05-2025
- Entertainment
- Yahoo
Gloria Trevi Soars With New ‘El Vuelo' Album & More Best New Music Latin
Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience. Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience. Yahoo is using AI to generate takeaways from this article. This means the info may not always match what's in the article. Reporting mistakes helps us improve the experience. Generate Key Takeaways New Music Latin is a compilation of the best new Latin songs and albums recommended by Billboard Latin and Billboard Español editors. Check out this week's picks below. Gloria Trevi, El Vuelo (Great Talent Records) More from Billboard Gloria Trevi is entering a new era of sorts, marked by the release of the first album under her new independent label. El Vuelo — all songs co-penned by the Mexican icon herself — serves as a testament to Trevi's ability to reinvent herself dabbling with new styles and genres without losing her core pop sound. The opening track 'Para Querer Como Te Quiero' is a bright cumbia and while that might be an indication that she may be going the regional Mexican route, she doesn't. Instead, she takes listeners on sonically varied journey: 'Mentí' is a little on the rock side, and opens with gorgeous classical arrangements, while 'Q.E.P.D.' fuses mariachi with very subtle reggaetón drums. In a world dominated by collabs, Trevi sticks to just one — featuring fellow pop diva Monica Naranjo on 'Para Siempre Triste.' While all songs take on different sounds, one thing is consistent throughout the album, and that is Trevi's knack for writing heart-wrenching lyrics about love, loss and freedom. — GRISELDA FLORES Adriel Favela, Danny Felix, Giovanny Ayala & Octavio Cuadras, Sueños de la Calle (Vol. 1) (Fonovisa Records) When four of the most exciting acts in música mexicana join forces, their shared roots help fuel a project that pushes the genre forward. On Sueños de la Calle (Vol. 1), Adriel Favela, Danny Felix, Giovanny Ayala, and Octavio Cuadras create a four-track EP that's personal and political. Rooted in the lived experiences of Mexican and Mexican American communities, the focus track '#SinMexicanos' delivers an unapologetic ode on immigration and identity. The song confronts the realities of labor, pride and resilience, with lines like 'el día que falten los mexicanos aquí en el gabacho se van a dar cuenta.' From the poetic grit of the title track to the heartfelt of 'X Ella,' the project blends accordion, tololoche, and storytelling with contemporary borderland perspectives. 'Sueños de la Calle (Vol. 1) is our way of telling what we live, what we feel, and what many out there don't dare to say,' the quartet says in a press release. 'Every song is born from the streets, the neighborhood, the border. Coming together was natural because we share the same roots, the same scars, and the same love for this music that gave us a voice.' — ISABELA RAYGOZA BORJA & Greeicy, 'Macarrones con Queso' (Virgin Music/BORJA) Short and sweet perfectly describes the first collaborative effort between BORJA and Greeicy. In 'Macarrones con Queso' (macaroni and cheese), the two Latin Grammy nominees beautifully harmonize together in every verse and chorus, backed by a tender, acoustic ballad produced by BORJA and Joel Iglesias. The conceptual tune revolves around two love birds who can't be together because they have different destinies. 'I found out you will be in town for a few days/ I've prepared for this moment since April/ Decorate your skin with kisses/ Cook macaroni and cheese/ And for dessert, maybe an eternity with you,' they kick off the track. 'But you have other plans and it's not me […] I have a feeling this is only another love song without ending,' they continue — in what could be the perfect soundtrack for a romance movie. — JESSICA ROIZ Alexis y Fido, 'Carita Triste' (Wild Dogz) Alexis y Fido return to the music scene with 'Carita Triste,' which showcases a vibrant electronic merengue infused with the distinctive signatures of the duo. The captivating track is a dynamic blend of reggaeton and rich Caribbean rhythms, painting a poignant narrative about young love that faces the challenges of social class divides. It also powerfully conveys the timeless message that love can triumph over societal obstacles. As Alexis y Fido celebrate two decades of their musical journey, this release also serves as a preview of new music they are crafting for 2025. — INGRID FAJARDO Check out more Latin recommendations this week below: Best of Billboard Sign up for Billboard's Newsletter. For the latest news, follow us on Facebook, Twitter, and Instagram.
